Molecular-Driven Treatment Advances in HER2+ Metastatic Colorectal Cancer
Host: Tanios S. Bekaii-Saab, MD
\n\n Guest: Joleen M. Hubbard, MD
\n\n\n \n
Are you familiar with the most recent clinical data surrounding the treatment of HER2-positive metastatic colorectal cancer? Listen in as Drs. Tanios Bekii-Saab and Joleen Hubbard talk about the recent approval of tucatinib and trastuzumab for the treatment of HER2-positive metastatic CRC and other therapies in development.